 Shares of Deciphera Pharmaceuticals Inc NASDAQ: DCPH tanked 75 on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp decline wiped millions off its market cap that now stands at 565 million. 